Varkaris, A., Pazolli, E., Gunaydin, H., Wang, Q., Pierce, L., Boezio, A. A., Bulku, A., DiPietro, L., Fridrich, C., Frost, A., Giordanetto, F., Hamilton, E. P., Harris, K., Holliday, M., Hunter, T. L., Iskandar, A., Ji, Y., Larivée, A., LaRochelle, J. R., … Kipp, D. R. (2023). Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia. Cancer Discovery, 14(2), 240–257. https://doi.org/10.1158/2159-8290.cd-23-0944
Publication Date
Columbia Affiliation
View